Cargando…

A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC

Rationale: Unlike traditional biopsy, liquid biopsy, which is a largely non-invasive diagnostic and monitoring tool, can be performed more frequently to better track tumors and mutations over time and to validate the efficiency of a cancer treatment. Circulating tumor cells (CTCs) are considered pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Minji, Park, Juhee, Lowe, Alarice C., Jeong, Hyoung-oh, Lee, Semin, Park, Hee Chul, Lee, Kyusang, Kim, Gwang Ha, Kim, Mi-Hyun, Cho, Yoon-Kyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196290/ https://www.ncbi.nlm.nih.gov/pubmed/32373206 http://dx.doi.org/10.7150/thno.44693

Ejemplares similares

Circulating tumor cells detected by lab-on-a-disc: Role in early diagnosis of gastric cancer
por: Kang, Hwa Mi, et al.
Publicado: (2017)

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
por: Lim, Minji, et al.
Publicado: (2018)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
por: Kejík, Zdeněk, et al.
Publicado: (2021)

Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients
por: Pirie-Shepherd, Steven R., et al.
Publicado: (2017)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
por: Serrano, Maria J., et al.
Publicado: (2014)

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
por: Cho, Jang Ho, et al.
Publicado: (2019)

Circulating Tumor Cell Clusters Are Cloaked with Platelets and Correlate with Poor Prognosis in Unresectable Pancreatic Cancer
por: Lim, Minji, et al.
Publicado: (2021)

The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment
por: Wei, Tengteng, et al.
Publicado: (2019)

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Detection of EGFR Mutations Using Bronchial Washing-Derived Extracellular Vesicles in Patients with Non-Small-Cell Lung Carcinoma
por: Park, Juhee, et al.
Publicado: (2020)

Pure CTCs, advanced WGS, and precise personalized combination therapies
por: Peters, Brock A., et al.
Publicado: (2017)

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
por: Carvalho, Ângela, et al.
Publicado: (2021)

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer
por: Xu, Ying, et al.
Publicado: (2023)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Lee, Hyun Woo, et al.
Publicado: (2020)

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
por: Hur, Jae Young, et al.
Publicado: (2018)

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs
por: Allen, Joshua E., et al.
Publicado: (2013)

ERBB signaling in CTCs of ovarian cancer and glioblastoma
por: Geethadevi, Anjali, et al.
Publicado: (2017)

CTCs 2020: Great Expectations or Unreasonable Dreams
por: Rossi, Elisabetta, et al.
Publicado: (2019)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
por: Kallergi, G., et al.
Publicado: (2018)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

EMT, CTCs and CSCs in tumor relapse and drug-resistance
por: Mitra, Abhisek, et al.
Publicado: (2015)

CTCs Expression Profiling for Advanced Breast Cancer Monitoring
por: Pereira-Veiga, Thais, et al.
Publicado: (2019)

Potential Use of CTCs as Biomarkers in Renal Cancer Patients
por: Bialek, Joanna, et al.
Publicado: (2022)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

Ex vivo expansion of circulating tumour cells (CTCs)
por: Mohamed, Bashir M., et al.
Publicado: (2023)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease
por: Shin, Sun Hye, et al.
Publicado: (2018)

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
por: Schochter, Fabienne, et al.
Publicado: (2019)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients
por: Kim, Yoonjung, et al.
Publicado: (2019)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
por: Liao, Bin-Chi, et al.
Publicado: (2020)

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma
por: Jeong, Hyoung-oh, et al.
Publicado: (2022)

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
por: Katsarou, Spyridoula D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uh5ogmt5kav29ci4nj0qigpd6g